Holen Sie sich die Stockscreener-App
0.3062
2.03%
0.0061
Handel nachbörslich:
.30
-0.0062
-2.02%
Schlusskurs vom Vortag:
$0.3001
Offen:
$0.3
24-Stunden-Volumen:
627.88K
Relative Volume:
0.19
Marktkapitalisierung:
$30.29M
Einnahmen:
$147.75M
Nettoeinkommen (Verlust:
$-284.23M
KGV:
-0.1045
EPS:
-2.93
Netto-Cashflow:
$-317.54M
1W Leistung:
-9.97%
1M Leistung:
-25.02%
6M Leistung:
-23.43%
1J Leistung:
-85.82%
1-Tages-Spanne:
$0.2945
$0.3106
1-Wochen-Bereich:
$0.28
$0.345
52-Wochen-Spanne:
$0.18
$2.15
Fibrogen Inc Stock (FGEN) Company Profile
Firmenname
Fibrogen Inc
Sektor
Branche
Telefon
415-978-1200
Adresse
350 BAY STREET, SAN FRANCISCO, CA
Vergleichen Sie FGEN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FGEN
Fibrogen Inc
|
0.3062 | 30.29M | 147.75M | -284.23M | -317.54M | -2.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Fibrogen Inc Stock (FGEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-08-08 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-06-26 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-06-26 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-06-26 | Herabstufung | Stifel | Buy → Hold |
| 2023-06-26 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-06-02 | Hochstufung | Stifel | Hold → Buy |
| 2023-01-31 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-01-26 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-09-22 | Herabstufung | Goldman | Neutral → Sell |
| 2021-08-20 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-07-16 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-07-16 | Herabstufung | Stifel | Buy → Hold |
| 2021-04-07 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2021-04-07 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-03-31 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-03-02 | Herabstufung | Jefferies | Buy → Hold |
| 2021-02-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-10-26 | Eingeleitet | Raymond James | Underperform |
| 2020-07-10 | Fortgesetzt | Stifel | Buy |
| 2020-05-01 | Eingeleitet | Cowen | Market Perform |
| 2020-04-27 | Eingeleitet | BofA/Merrill | Neutral |
| 2019-05-29 | Fortgesetzt | Goldman | Neutral |
| 2019-05-10 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2019-04-12 | Eingeleitet | Piper Jaffray | Neutral |
| 2019-02-11 | Fortgesetzt | Stifel | Buy |
| 2018-12-19 | Hochstufung | Citigroup | Neutral → Buy |
| 2017-08-08 | Bestätigt | Leerink Partners | Outperform |
| 2017-08-08 | Bestätigt | Stifel | Buy |
| 2017-07-21 | Herabstufung | Goldman | Buy → Neutral |
| 2017-07-11 | Eingeleitet | Jefferies | Buy |
| 2016-02-11 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2016-01-21 | Eingeleitet | Credit Suisse | Neutral |
| 2015-12-04 | Eingeleitet | Citigroup | Buy |
| 2015-09-23 | Eingeleitet | Lake Street | Hold |
| 2015-07-29 | Eingeleitet | Citigroup | Buy |
| 2015-07-20 | Hochstufung | Goldman | Neutral → Buy |
| 2014-12-09 | Eingeleitet | Stifel | Buy |
Alle ansehen
Fibrogen Inc Aktie (FGEN) Neueste Nachrichten
FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
FibroGen extends merger option deadline with Fortis By Investing.com - Investing.com Australia
FibroGen extends merger option deadline with Fortis - Investing.com India
Morgan Stanley’s Adam Jonas Is Pounding the Table on This 1 ‘Unique’ Stock - The Globe and Mail
FibroGen reports promising FG-3246 study results for prostate cancer - Investing.com
FibroGen Announces Publication of Results from Phase 1 - GlobeNewswire
1 Top Cryptocurrency to Buy Before It Soars 14,623%, According to Michael Saylor - The Globe and Mail
Fibrogen CEO Wettig Thane buys $50,663 in common stock By Investing.com - Investing.com Australia
Fibrogen CEO Wettig Thane buys $50,663 in common stock - Investing.com India
Fibrogen director James Schoeneck buys $105,040 in stock By Investing.com - Investing.com Canada
In the Red? AstraZeneca Acquires FibroGen, Inc.’s China Subsidiary - Law Street Media
FibroGen, Inc. (NASDAQ:FGEN) Q4 2024 Earnings Call Transcript - Insider Monkey
FibroGen Full Year 2024 Earnings: Beats Expectations - Yahoo
FibroGen Inc (FGEN) Q4 2024 Earnings Call Highlights: Navigating Revenue Declines with ... - Yahoo Finance
FibroGen Inc (FGEN) Q4 2024 Earnings Call Highlights: Navigating Revenue Declines with ... By GuruFocus - Investing.com Canada
FibroGen Inc (FGEN) Q4 2024 Earnings Call Highlights: Navigating Revenue Declines with Strategic Initiatives - GuruFocus.com
FibroGen Announces Strategic Sale and Financial Outlook - TipRanks
FibroGen: Q4 Earnings Snapshot - mySA
Earnings call transcript: FibroGen reports Q4 2024 EPS beat, stock dips - Investing.com Canada
Earnings call transcript: FibroGen reports Q4 2024 EPS beat, stock dips By Investing.com - Investing.com South Africa
FibroGen Inc earnings beat by $0.35, revenue fell short of estimates - Investing.com Canada
FibroGen Inc reports results for the quarter ended December 31Earnings Summary - TradingView
FibroGen Inc Reports Q4 2024 Earnings: EPS Loss of $0.08 Beats E - GuruFocus
FIBROGEN Earnings Results: $FGEN Reports Quarterly Earnings - Nasdaq
FIBROGEN INC SEC 10-K Report - TradingView
FibroGen, Inc. Announces Sale of FibroGen China to AstraZeneca for $160 Million and Updates on Clinical Trials - Nasdaq
FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
FibroGen's Strategic $160M China Exit Extends Cash Runway to 2027 Amid Latest Earnings - StockTitan
FIBROGEN Earnings Preview: Recent $FGEN Insider Trading, Hedge Fund Activity, and More - Nasdaq
StockNews.com Initiates Coverage on FibroGen (NASDAQ:FGEN) - Defense World
Weekly CEO Buys Highlight: Camping World, FibroGen - GuruFocus.com
AstraZeneca’s $160 Million Acquisition of FibroGen China - Global Legal Chronicle
Ropes & Gray Advises FibroGen in $160 Million Sale of Fibrogen China to AstraZeneca - Ropes & Gray LLP
FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
FibroGen, Inc. to Announce Q4 and Full Year 2024 Financial Results on March 17 - Nasdaq
When Will FibroGen Reveal Its 2024 Performance? Key Date for Investors Announced - StockTitan
FibroGen, Inc. to Host Earnings Call - ACCESS Newswire
FibroGen announces $30M "at the market" equity offering - Investing.com India
FibroGen announces $30M "at the market" equity offering By Investing.com - Investing.com South Africa
FibroGen Says Entered ATM Equity Offering Sales Agreement Relating To Sale From Time To Time Of Shares Of Common Stock - Marketscreener.com
Form 424B5 FIBROGEN INC - StreetInsider.com
Asia Deal Watch: AstraZeneca Buys FibroGen’s Chinese Subsidiary - insights.citeline.com
FibroGen Inc Announces Sale of China Subsidiary to AstraZeneca f - GuruFocus.com
Investor Network: FibroGen, Inc. to Host Earnings Call - ACCESS Newswire
FibroGen sells China biz to AstraZeneca for $160 M - BSA bureau
Finanzdaten der Fibrogen Inc-Aktie (FGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):